Treatment of early-stage supradiaphragmatic Hodgkin's lymphoma;Lymphome de Hodgkin: Traitement des stades localisés sus-diaphragmatiques

Oncologie

Volumn 10, Issue 5, 2008, Pages 303-306

  Ferme C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

18F deoxyglucose positron emission tomography; Chemotherapy; Hodgkin's lymphoma; Radiotherapy

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; VINBLASTINE;

CANCER RADIOTHERAPY; CANCER STAGING; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EARLY CANCER; EARLY RESPONSE GENE; HODGKIN DISEASE; HUMAN; RADIATION DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 45749152179     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-008-0836-0     Document Type: Review

References (23)

1. André M, Brice P, Cazals D, et al. (1997) Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stages I, II and III). Hematol Cell Ther 39: 59-65
2. Bonadonna G, Bonfante V, Viviani S, et al. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22: 2835-2841
3. Brusamolino E, Lazzarino M, Orlandi E, et al. (1994) Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol 5(suppl 2): 1001-1006
4. Duggan D, Petroni GR, Johnson JL, et al. (2003) Randomized comparison of ABVD and MOPP-ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21: 607-614
5. Eghbali H, Brice P, Creemers GY, et al. (2005) Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial. Blood 106: 240a (Abstr. 814)
6. Eghbali H, Raemaekers J, Carde P (2005) EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol 66(suppl): 135-140
7. Engert A, Franklin J, Eich HT, et al. (2007) Two cycles of doxorubicin, bleomycin, vonblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25: 3495-3502
8. Engert A, Schiller P, Josting A, et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stages unfavourable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21: 3601-3608
9. Fermé C, Diviné M, Vranovsky A, et al. (2005) Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial. Blood 106: 240a (Abstr. 813)
10. Fermé C, Eghbali H, Meerwaldt JH, et al. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357: 1916-1927
11. Gallamini A, Hutchings M, Rigacci L, et al. (2007) Early interim 2-[18F] Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a Joint Italian-Danish Study. J Clin Oncol 25: 3746-3752
12. Girinsky T, Van der Maazen R, Specht L (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79: 270-277
13. Gisselbrecht C, Mounier N, André M, et al. (2005) How to define intermediate-stage in Hodgkin's lymphoma? Eur J Haematol Suppl (66): 111-114
14. Horning SJ, Hoppe RT, Breslin S, et al. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20: 630-637
15. Hutchings M, Loft A, Hansen M, et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107: 52-59
16. Klimm BD, Engert A, Brillant C, et al. (2005) Comparison of BEACOPP and ABVD chemotherapy in intermediate-stage Hodgkin's lymphoma: results of the fourth interim analysis of the HD11 trial of GHSG. Proc Am Soc Clin Oncol 23: 6507 (Abstr. 6507)
17. Meyer RM, Gospodarowicz MK, Connors JM, et al. (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stages Hodgkin's lymphoma: National Cancer Institute of Canada Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23: 4634-4642
18. Müller RP, Eich HT (2007) Dose and field size, the GHSG experience. Haematologica 92(Suppl 5): 18 (Abstr. 1058)
19. Noordijk EM, Carde P, Dupouy N, et al. (2006) Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24: 3128-3135
20. Press OW, LeBlanc M, Lichter AS, et al. (2001) Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19: 42-44
21. Rehan FA, Brillant C, Schulz H, et al. (2007) Chemotherapy alone versus chemotherapy plus radiotherapy for early-stage Hodgkin lymphoma. Blood 110: 686a (Abstr. 2320)
22. Strauss DJ, Portlock CS, Qin J, et al. (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II and IIA nonbulky Hodgkin disease. Blood 104: 3483-3489
23. Zittoun R, Audebert A, Hoerni B, et al. (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early-stages of Hodgkin's disease. J Clin Oncol 3: 207-214